
**LAURUS LABS LTD. Q2 & H1 FY2019 RESULTS CONFERENCE CALL
ON FRIDAY, NOVEMBER 02, 2018 AT 4:00 PM IST**

Laurus Labs Ltd. (Laurus), a leading research and development driven pharmaceutical company in India, will organize a conference call for Investors and Analysts, on Friday, November 02, 2018 at 4:00 pm IST.

The conference call will be initiated with a brief management discussion on the Q2 & H1 FY2019 results which will be declared on November 01, 2018. This will be followed by an interactive Question & Answer session. The call will be hosted by Kotak Institutional Equities.

Details of the conference call are as follows:

Timing	4:00 pm IST on Friday, November 02, 2018
Conference dial-in	
Primary number	+91 22 6280 1214
Secondary Number	+91 7045671221 <i>Available all over India</i>
Singapore Number	6531575746
Hong Kong Number	85230186877
USA Number	13233868721
UK Number	442034785524

- ENDS -

 

About Laurus Labs Ltd.

Laurus Labs is a leading research and development driven pharmaceutical company in India. The Company has grown consistently to become one of the leading manufacturers of Active Pharmaceutical Ingredients (APIs) for anti-retroviral (ARV) and Hepatitis C. Laurus also manufactures APIs in Oncology and other therapeutic areas. Its strategic and early investments in R&D and manufacturing infrastructure have enabled it to become one of the leading suppliers of APIs in the ARV therapeutic area. Laurus Labs also forayed into Finished Dosages Forms capabilities on the back of existing strengths in APIs. The Company is also driving growth opportunities in the Synthesis and Ingredients businesses. **Corporate Identification No: L24239AP2005PLC047518.**

For further information please contact

Monish Shah

Laurus Labs Limited

Tel: +91 40 3980 4366

Email: monish.shah@LaurusLabs.Com

Pavan Kumar Nerella

Laurus Labs Limited

Tel: +91 40 3980 4380

Email: pavankumar.n@lauruslabs.com

 